About: Estradiol valerate/Dienogest     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
http://linked.open...gbank/description
  • Estradiol valerate/Dienogest is a Combined oral contraceptive (COC) indicated for use by women to prevent pregnancy. It is also indicated for the treatment of heavy menstrual bleeding in women. The efficacy of Estradiol valerate/Dienogest in women with a body mass index of >30 kg/m2 has not been evaluated. (en)
http://linked.open...y/drugbank/dosage
http://linked.open...generalReferences
  • # Whalen KL, Rose R: Estradiol valerate/dienogest: a novel oral contraceptive. Ann Pharmacother. 2011 Oct;45(10):1256-61. doi: 10.1345/aph.1Q216. Epub 2011 Sep 13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21917554 # Wasiak R, Filonenko A, Vanness DJ, Law A, Jeddi M, Wittrup-Jensen KU, Stull DE, Siak S, Jensen JT: Impact of estradiol valerate/dienogest on work productivity and activities of daily living in women with heavy menstrual bleeding. J Womens Health (Larchmt). 2013 Apr;22(4):378-84. doi: 10.1089/jwh.2012.3633. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23586801 # Ruan X, Seeger H, Mueck AO: The pharmacology of dienogest. Maturitas. 2012 Apr;71(4):337-44. doi: 10.1016/j.maturitas.2012.01.018. Epub 2012 Feb 24. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22364708 # Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M: Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Contraception. 2012 Aug;86(2):96-101. doi: 10.1016/j.contraception.2011.11.011. Epub 2012 Jan 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22240178 (en)
http://linked.open...gy/drugbank/group
  • approved (en)
http://linked.open...drugbank/halfLife
  • The terminal half-life of estradiol is approximately 14 hours. The terminal half-life of dienogest is approximately 11 hours. (en)
http://linked.open...ugbank/indication
  • Indicated for use by women for pregnancy prevention. Also indicated for the treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of birth control. (en)
sameAs
Title
  • Estradiol valerate/Dienogest (en)
adms:identifier
http://linked.open...mechanismOfAction
  • Estradiol valerate/Dienogest lower the risk of becoming pregnant primarily by suppressing ovulation. Additionally, cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation are other possible mechanisms. (en)
http://linked.open...outeOfElimination
  • Estradiol and its metabolites are mainly excreted in urine, with about 10% being excreted in the feces. Dienogest is primarily excreted renally in the form of metabolites and unchanged dienogest is the dominating fraction in plasma. (en)
http://linked.open.../drugbank/synonym
  • 17-hydroxy-3-oxo-19-nor-17α-pregna-4,9-diene-21-nitrile (en)
  • 17β-Estradiol-17-valerate (en)
  • pentanoate d'estra-1,3,5(10)-triène-3-ol-17β-yle (en)
  • 17α-cyanomethyl-17β-hydroxy-estra-4,9(10)-dien-3-one (en)
http://linked.open...umeOfDistribution
  • In serum, 38% of estradiol is bound to sex hormone-binding globulin (SHBG), 60% to albumin and 2–3% circulates in free form. An apparent volume of distribution of approximately 1.2 L/kg was determined after intravenous (IV) administration. (en)
http://linked.open...k/foodInteraction
  • Grapefruit juice may increase plasma concentrations of dienogest. (CYP3A4 inhibitor) (en)
http://linked.open...nk/proteinBinding
  • ~90% (en)
http://linked.open...ynthesisReference
  • Miescher, K . and Scholz, C.; U.S. Patent 2,205,627; June 25, 1940; assigned to the Society of Chemical Industry in Basle, Switzerland. Miescher, K. and Scholz, C.; U.S. Patent 2,233,025; February 25,1941; assigned to Ciba Pharmaceutical Products, Incorporated. (en)
foaf:page
http://linked.open...ugbank/IUPAC-Name
http://linked.open...gy/drugbank/InChI
http://linked.open...Molecular-Formula
http://linked.open.../Molecular-Weight
http://linked.open...noisotopic-Weight
http://linked.open...y/drugbank/SMILES
http://linked.open.../Water-Solubility
http://linked.open...ogy/drugbank/logP
http://linked.open...ogy/drugbank/logS
http://linked.open...nd-Acceptor-Count
http://linked.open...-Bond-Donor-Count
http://linked.open...drugbank/InChIKey
http://linked.open...urface-Area--PSA-
http://linked.open...nk/Polarizability
http://linked.open...bank/Refractivity
http://linked.open...atable-Bond-Count
http://linked.open.../affectedOrganism
  • Humans and other mammals (en)
http://linked.open...casRegistryNumber
  • 65928-58-7 (en)
http://linked.open...k/Bioavailability
http://linked.open...bank/Ghose-Filter
http://linked.open...nk/MDDR-Like-Rule
http://linked.open...ank/Melting-Point
http://linked.open...k/Number-of-Rings
http://linked.open...siological-Charge
http://linked.open...bank/Rule-of-Five
http://linked.open...tional-IUPAC-Name
http://linked.open...strongest-acidic-
http://linked.open...-strongest-basic-
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 47 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software